Biosimilars Market by Product (Insulin, Filgrastim, Interferons, rHGH), Glycosylated (Monoclonal Antibodies, EPO), Peptides (Glucagon, Calcitonin)) & Application - Global Forecast to 2020.

Description: Biosimilars Market by Product (Recombinant Non-Glycosylated Proteins (Insulin, Filgrastim, Interferons, rHGH), Glycosylated (Monoclonal Antibodies, EPO), Peptides (Glucagon, Calcitonin)) & Application (Oncology, Blood Disorders) - Global Forecast to 2020.

Various factors have contributed to the rise in demand for biopharmaceutical products such as biologics and biosimilars. Some of these factors include the rising pressure to reduce healthcare expenditure, growing demand for cost-effective alternatives, growing burden of chronic diseases, and growing aging population. Biosimilars are similar versions of their corresponding patented biologic drugs, and are similar with regards to their quality, safety, and efficacy. The global biosimilars market is estimated to be worth $2.29 billion in 2015, and is poised to grow at a CAGR of 22.1% during the forecast period.

This report studies and analyzes the biosimilars market by product and application. On the basis of products, the biosimilars market is segmented into recombinant nonglycosylated proteins, recombinant glycosylated proteins, and recombinant peptides. The recombinant nonglycosylated proteins market is further segmented into insulin, granulocyte colony-stimulating factor (G-CSF), interferons, and human growth hormones; whereas, the recombinant glycosylated proteins market is further segmented into erythropoietin, monoclonal antibodies, and follitropin. The recombinant peptides market is segmented into calcitonin and glucagon. The recombinant glycosylated proteins segment is expected to witness the highest growth rate owing to the increased demand for monoclonal antibodies in the treatment of cancer (oncology), autoimmune disorders, blood disorders, and infectious diseases. On the other hand, the recombinant nonglycosylated proteins segment accounts for the largest share of the market in 2015. The insulin segment is poised to be the fastest-growing segment of the recombinant nonglycosylated proteins market, growing at a CAGR of 28.1% from 2015 to 2020. Growth in this insulin market is attributed to the rising incidences of diabetes; ongoing patent expirations of biologic drugs such as Lantus, Humalog, and Novorapid; and the cost effectiveness of insulin.

On the basis of applications, the biosimilars market is segmented into oncology, blood disorders, growth hormonal deficiency, chronic and autoimmune disorders, and other applications (female infertility, hypoglycemia, myocardial infarction, postmenopausal osteoporosis, and chronic kidney failure).

Geographically, Europe is expected to account for the largest share of the global biosimilars market in 2015 followed by Asia-Pacific. The large share of the European region can be attributed to the rising budgetary pressures to reduce healthcare expenditure, increasing aging population, growing demand for cost-effective alternatives, rising incidences of various diseases, and government initiatives. On the other hand, stringent regulatory environment, high manufacturing complexities and costs, and high-entry barriers are considered to hinder its market growth.

The global biosimilars market is highly competitive, with a large number of big and small market players. As of 2014, the global biosimilars market was dominated by Sandoz International GmbH (Germany), Hospira, Inc. (U.S.), and Teva Pharmaceutical Industries Ltd. (Israel). Furthermore, new product launches and expansions are the major strategies adopted by major players to achieve growth in this market.

Reasons to Buy the Report:

From an insight perspective, this research report focused on various levels of analysis—industry analysis (industry trends and Porter’s five forces model), market share analysis of top players, and company profiles, which together comprise and discuss the basic views on the competitive landscape; emerging and high-growth segments in the biosimilars market; and high-growth regions/countries and their respective regulatory policies, government initiatives, drivers, restraints, and opportunities.

The report will enrich both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn will help the firms in garnering a greater market share. Firms purchasing the report
could use any one or combination of the below-mentioned five strategies (market penetration, product development/innovation, market development, market diversification, and competitive assessment) for strengthening their market shares.

The report provides insights on the following pointers:

- **Market Penetration**: Comprehensive information on biosimilar products offered by the top 10 players in the biosimilars market. The report analyzes the biosimilars market by product and application across geographies.

- **Product Development/Innovation**: Detailed insights on research and development activities and new product launches in the biosimilars market.

- **Market Development**: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various biosimilar products across geographies.

- **Market Diversification**: Exhaustive information about new products, untapped geographies, recent developments, and investments in the biosimilars market.

- **Competitive Assessment**: In-depth assessment of market shares, strategies, products, distribution networks, and manufacturing capabilities of leading players in the biosimilars market.

Contents:

1 Introduction
   1.1 Objectives Of The Study
   1.2 Market Definition
   1.3 Market Scope
      1.3.1 Market Segmentation
      1.3.2 Years Considered For The Study
   1.4 Currency
   1.5 Limitations
   1.6 Stakeholders

2 Research Methodology
   2.1 Market Size Estimation
   2.2 Market Breakdown And Data Triangulation
   2.3 Market Share Estimation
      2.3.1 Key Data From Secondary Sources
      2.3.2 Key Data From Primary Sources
      2.3.2.1 Key Industry Insights
      2.4 Assumptions For The Study

3 Executive Summary
   3.1 Introduction

4 Premium Insights
   4.1 Overall Biosimilars Market
   4.2 Biosimilars Market, By Type & Region
   4.3 Biosimilars Market, By Countries
   4.4 Recombinant Nonglycosylated Proteins Market, By Type
   4.5 Lifecycle Analysis, By Region

5 Market Overview
   5.1 Introduction
   5.2 Biosimilars Market Segmentation
      5.2.1 By Product
      5.2.2 By Application
      5.2.3 By Region
   5.3 Market Dynamics
      5.3.1 Drivers
      5.3.1.1 Growing Pressure To Curtail Healthcare Expenditure
      5.3.1.2 Increasing Demand For Biosimilar Drugs Due To Their Cost-Effectiveness
      5.3.1.3 Rising Incidences Of Diseases
5.3.1.4 Rise In Aging Population Triggers The Incidences Of Chronic Disorders
5.3.1.5 Strategic Collaborations Lead To Enhance Productivity And Clinical Trial Activities For Biosimilars
5.3.1.6 Increasing Government Support And Initiatives To Develop And Promote Biosimilars
5.3.2 Restraints
5.3.2.1 High Manufacturing Complexities And Costs
5.3.2.2 Innovative Strategies By Biologic Drug Manufacturers
5.3.3 Opportunities
5.3.3.1 Emerging Markets
5.3.3.2 Untapped Indications
5.3.3.3 Biologic Products Set To Be Off-Patent Will Offer Opportunities For Biosimilars
5.3.4 Challenges
5.3.4.1 Stringent Regulatory Requirements To Adversely Affect Investments In Biosimilars
5.3.5 Burning Issues
5.3.5.1 Product Withdrawals Provide Significant Opportunities For New Entrants

6 Industry Insights
6.1 Introduction
6.2 Porter'S Five Forces Analysis
6.2.1 Threat Of New Entrants
6.2.2 Threat Of Substitutes
6.2.3 Intensity Of Rivalry
6.2.4 Bargaining Power Of Suppliers
6.2.5 Bargaining Power Of Buyers
6.3 Key Pipeline Products
6.4 Regulatory Outlook
6.4.1 North America
6.4.1.1 U.S.
6.4.1.2 Canada
6.4.2 Europe
6.4.3 Asia-Pacific
6.4.3.1 China
6.4.3.2 India
6.4.3.3 Japan
6.4.3.4 South Korea
6.4.4 Rest Of The World
6.4.4.1 Brazil
6.4.4.2 Mexico
6.4.4.3 Argentina
6.4.4.4 Saudi Arabia
6.5 Biosimilars Services Industry Insights
6.5.1 Introduction
6.5.2 Contract Manufacturing Organizations
6.5.3 Contract Research Organizations
6.5.4 Other Services (Nonclinical & Bioinformatics)

7 Biosimilars Market, By Type Of Product
7.1 Introduction
7.2 Recombinant Non-Glycosylated Proteins
7.2.1 Insulin
7.2.2 Recombinant Human Growth Hormone (RHGH)
7.2.3 Granulocyte Colony-Stimulating Factor (Filgrastim)
7.2.4 Interferons
7.3 Recombinant Glycosylated Proteins
7.3.1 Erythropoietin (Epo)
7.3.2 Monoclonal Antibodies (Mabs)
7.3.3 Folitropin
7.4 Recombinant Peptides
7.4.1 Glucagon
7.4.2 Calcitonin

8 Biosimilars Market, By Application
8.1 Introduction
8.2 Oncology
8.3 Blood Disorders
8.4 Chronic And Autoimmune Diseases
8.5 Growth Hormone Deficiency
8.6 Infectious Diseases
8.7 Other Applications

9 Biosimilars Market, By Region
9.1 Introduction
9.2 North America
9.2.1 U.S.
9.2.2 Canada
9.3 Europe
9.3.1 U.K.
9.3.2 Germany
9.3.3 France
9.3.4 Spain
9.3.5 Italy
9.3.6 Rest Of Europe
9.4 Asia-Pacific
9.4.1 China
9.4.2 India
9.4.3 Japan
9.4.4 South Korea
9.4.5 Rest Of Asia-Pacific (ROAP)
9.5 Rest Of The World (Row)

10 Competitive Landscape
10.1 Overview
10.2 Market Share Analysis
10.3 Competitive Situation And Trends
10.3.1 New Product Launches And Regulatory Approvals
10.3.2 Agreements And Collaborations
10.3.3 Expansions
10.3.4 Acquisitions
10.3.5 Other Developments

11 Company Profiles
(Overview, Financials, Products & Services, Strategy, & Developments)*
11.1 Introduction
11.2 Hospira, Inc.
11.3 Sandoz International GMBH (A Division Of Novartis International Ag)
11.4 Teva Pharmaceutical Industries Ltd.
11.5 Roche Diagnostics (A Division Of F. Hoffmann-La Roche Ltd.)
11.6 Amgen
11.7 Biocon Ltd.
11.8 Dr. Reddy's Laboratories
11.9 Celltrion Inc.
11.10 Mylan Inc.
11.11 Merck Kgaa

*Details On Financials, Product & Services, Strategy, & Developments Might Not Be Captured In Case Of Unlisted Companies.

12 Appendix
12.1 Insights From Industry Experts
12.2 Discussion Guide
12.3 Introducing Rt: Real-Time Market Intelligence
12.4 Available Customizations
12.5 Related Reports

List Of Tables

Table 1 Biosimilars Market: Major Collaborations (2012-2015)
Table 2 Biologics Going Off-Patent To Boost The Market Growth For Biosimilars
Table 3 High Manufacturing Complexities And Costs Restraining The Growth For The Biosimilars Market
Table 4 List Of Key Biologics Under The Threat Of Patent Expiry
Table 5 Growth Prospects In Emerging Markets Fuel The Market Growth
Table 6 Stringent Regulatory Requirements In Major Countries Is A Major Challenge For The Biosimilars Market
Table 7 Biosimilars In Clinical Trials
Table 8 Status Of Regulatory Pathway In North America Region
Table 9 Substitution Status In European Countries
Table 10 Status Of Regulatory Pathway In The Asia-Pacific Region
Table 11 Status Of Regulatory Pathway In The Row
Table 12 Joint Ventures Between Cmos & Pharmaceutical Companies For Biosimilars
Table 13 Biosimilars Market Size, By Product Type, 2013–2020 ($Million)
Table 14 Recombinant Non-Glycosylated Proteins Market Size, By Type, 2013–2020 ($Million)
Table 15 Recombinant Non-Glycosylated Proteins Market Size, By Region, 2013–2020 ($Million)
Table 16 North America: Recombinant Non-Glycosylated Proteins Market Size, By Country, 2013–2020 ($Million)
Table 17 Europe: Recombinant Non-Glycosylated Proteins Market Size, By Country, 2013–2020 ($Million)
Table 18 Asia-Pacific: Recombinant Non-Glycosylated Proteins Market Size, By Country, 2013–2020 ($Million)
Table 19 Insulin Market Size, By Region, 2013–2020 ($Million)
Table 20 Recombinant Human Growth Hormone Market Size, By Region, 2013–2020 ($Million)
Table 21 List Of Approved Products From 2012 To 2015.
Table 22 Granulocyte Colony-Stimulating Factor Market Size, By Region, 2013–2020 ($Million)
Table 23 Interferons Market Size, By Region, 2013–2020 ($Million)
Table 24 Recombinant Glycosylated Proteins Market Size, By Type, 2013–2020 ($Million)
Table 25 Recombinant Glycosylated Proteins Market Size, By Region, 2013–2020 ($Million)
Table 26 North America: Recombinant Glycosylated Proteins Market Size, By Country, 2013–2020 ($Million)
Table 27 Europe: Recombinant Glycosylated Proteins Market Size, By Country, 2013–2020 ($Million)
Table 28 Asia-Pacific: Recombinant Glycosylated Proteins Market Size, By Country, 2013–2020 ($Million)
Table 29 Erythropoietin Market Size, By Region, 2013–2020 ($Million)
Table 30 Monoclonal Antibodies Market Size, By Region, 2013–2020 ($Million)
Table 31 Follitropin Market Size, By Region, 2013–2020 ($Million)
Table 32 Recombinant Peptides Market Size, By Type, 2013–2020 ($Million)
Table 33 Recombinant Peptides Market Size, By Region, 2013–2020 ($Million)
Table 34 North America: Recombinant Peptides Market Size, By Country, 2013–2020 ($Million)
Table 35 Europe: Recombinant Peptides Market Size, By Country, 2013–2020 ($Million)
Table 36 Asia-Pacific: Recombinant Peptides Market Size, By Country, 2013–2020 ($Million)
Table 37 Glucagon Market Size, By Region, 2013–2020 ($Million)
Table 38 Calcitonin Market Size, By Region, 2013–2020 ($Million)
Table 39 Biosimilars Market Size, By Application, 2012–2019 ($Million)
Table 40 Biosimilars Market Size For Oncology, By Region, 2012–2019 ($Million)
Table 41 Biosimilars Market Size For Blood Disorders, By Region, 2012–2019 ($Million)
Table 42 Biosimilars Market Size For Chronic And Autoimmune Diseases, By Region, 2012–2019 ($Million)
Table 43 Biosimilars Market Size For Growth Hormone Deficiency, By Region, 2012–2019 ($Million)
Table 44 Biosimilars Market Size For Infectious Diseases, By Region, 2012–2019 ($Million)
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

| Product Name: | Biosimilars Market by Product (Insulin, Filgrastim, Interferons, rHGH), Glycosylated (Monoclonal Antibodies, EPO), Peptides (Glucagon, Calcitonin)) & Application - Global Forecast to 2020. |
| Web Address: | http://www.researchandmarkets.com/reports/3315099/ |
| Office Code: | SCBR8F83 |

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Quantity</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User:</td>
<td>USD 5650</td>
</tr>
<tr>
<td>Electronic (PDF) - 1 - 5 Users:</td>
<td>USD 6650</td>
</tr>
<tr>
<td>Electronic (PDF) - Site License:</td>
<td>USD 8150</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide:</td>
<td>USD 10000</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

<table>
<thead>
<tr>
<th>Title:</th>
<th>Mr</th>
<th>Mrs</th>
<th>Dr</th>
<th>Miss</th>
<th>Ms</th>
<th>Prof</th>
</tr>
</thead>
<tbody>
<tr>
<td>First Name:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Email Address: *</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Job Title:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Organisation:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Address:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>City:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Postal / Zip Code:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Country:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Phone Number:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fax Number:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: ____________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World